<DOC>
	<DOC>NCT01847989</DOC>
	<brief_summary>This trial was conducted in Europe. The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Normal platelet count and clotting parameters Adequate renal and hepatic function If female and of childbearing potential, negative serum pregnancy test within 21 days of enrollment and a negative urine pregnancy test on admission to the clinical research unit If a sexually active male or a sexually active female of childbearing potential,agreement to use a medically accepted form of contraception from the time of enrollment to completion of all followup study visits Negative drug and alcohol screens Known antibodies or hypersensitivity to FXIII Known bleeding or hematologic disorder Known allergy to yeast Receipt of blood products within 30 days of screening Donation of blood within 30 days prior to enrollment Any surgical procedure in the 30 days prior to enrollment Previous history of autoimmune disorders involving autoantibodies, e.g., systemic lupus erythematosus Receipt of treatment with any experimental agent within 30 days of study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>